**Published Standard Number 1 – Applications (National)**

| Application number | Application type | Number of applications | Performance | Target days |
|---|---|---|---|---|
| 1 | Complex timetable (National new MA applications) Complex new MA applications, e.g. novel therapies, new actives | 25 | 100% | 210.0 |
| 2 | Major timetable (National) New MRLs. All other MA applications (excl. MAPI and Copycats) | 8 | 100% | 180.0 |
| 3 | Standard timetable (National Type II variations. New MA - MAPIs and Copycats. New VHRs) | 80 | 100% | 120.0 |
| 4 | Shortened timetable (Type IB variations. New ATC (type B). Out of Scope MRLs) | 154 | 81.2% | 60.0 |
| 5 | Minor timetable (National) Type IA variations. Administrative Type IB variations. New ATC (Type A/S). ATC variations and renewals. | 686 | 87.2% | 30.0 |
| 6 | Parallel Assessment with EU Procedures | 377 | 99.2% | - |
| 7 | Shared Assessment with International Partners | 1 | 100% | - |
| 8 | Batch timetable (National) specific Batch Control | 53 | 100% | 20.0 |
| 9 | Autogenous Vaccines. New & Variations | 5 | 100% | 45.0 |

**Published Standard Number 1 – Applications (Other)**

| Application number | Application Type | Number of applications | Performance |
|---|---|---|---|
| 10 | Mock-up period completed within 20 days (or up to 40 days for parallel applications involving different QRD sources) | 472 | 96% |
| 11 | Validation | 910 | 40.3% |
| 12 | Issue of authorised documentation | 1672 | 22.5% |

**Published Standard Number 1 – Applications (European - NI)**

| Application number | Application Type | Number of applications | Performance |
|---|---|---|---|
| 13 | New Decentralised (DCP) | 7 | 100% |
| 14 | New Mutual Recognition (MRP) | 7 | 100% |
| 15 | MRP Variations (Type IB & II) | 268 | 100% |

**Published Standard Number 2 – Public Assessment Reports**

| Application number | Application type | Total number | Performance |
|---|---|---|---|
| 16 | Publishing Summary of Product Characteristics (SPCs) | 84 | 100% |
| 17 | Publishing Public Assessment Reports (PuARs) | 28 | 100% |
| 18 | Updating PuARs | 5 | 100% |

**Published Standard Number 3 – Quality of Documentation**

| Application number | Application type | Number of applications | Performance |
|---|---|---|---|
| 19 | Unreturned Documents | 2611 | 97.4% |

**Published Standard Number 4 – Product Defects**

| Task number | Task | Number of tasks | Performance |
|---|---|---|---|
| 20 | Product Defects reports | 33 | 100% |
| | High risk <5 days | 2 | - |
| | Low risk <10 days | 31 | - |

**Published Standard Number 5 – Import, Export and Batch Release Schemes**

| Application number | Application Type | No of Apps | Performance | Target Days |
|---|---|---|---|---|
| 21 | Applications for new products | 124 | 98.4% | 15/25 |
| 22 | Applications for previously imported products | 174 | 99% | 15 |
| 23 | All other urgent applications | 232 | 99.5% | - |
| | Urgent | 0 | | 2 |
| | Non Urgent | 232 | | 10 |
| 24 | Instant Import Certificates | 20,960 | - | - |
| 25 | Export | 121 | 100% | 10 |
| 26 | Batch Release | 1260 | 99.3% | 10 |

**Published Standard Number 6 – Pharmacovigilance**

| Task number | Task | No. | Performance |
|---|---|---|---|
| 27 | Human, Animal & Environmental AERs | 2299 | 93.1% |
| 28 | PSURs | 844 | 100% |
| 29 | Inspections | 10 | 90% |

### Published Standard Number 7– Inspections

| Task number | Task | No. | Performance | Target Days |
|---|---|---|---|---|
| 30 | Inspections within 3 years (GMP) | 15 | 100% | - |
| | Within 5 years (GDP) of last inspection | 14 | Joint with above | - |
| 31 | Inspection Deficiency Reports | 24 | 100% | 30.0 |
| 32 | (GMP) Certificates or (GDP) final reports sent | 27 | 100% | 90.0 |
| 33 | Approval of new Feed business operators and SQP retailer sites | 29 | 100% | 45.0 |
| 34 | Final inspection report to Feed business operators and SQP retailers | 171 | 100% | 30.0 |

### Published Standard Number 8 – Enforcement

| Task number | Task | No. | Performance |
|---|---|---|---|
| 35 | Quarterly VMR Breaches | 2 | 100% |
| 36 | Intelligence Activity | 20 | 100% |

### Published Standard Number 9 – Residues

| Task number | Task | No. | Performance |
|---|---|---|---|
| 37 | Quarterly Non-Compliance Data | 1 | 100% |
| 38 | Sample Testing | 16,889 | 99.8% |

### Additional information

The VMD continuously monitors all targets and puts in place countermeasures, where possible, to ensure targets are met.